Globus Medical (GMED) Q2 Revenue Up 18%
Globus Medical (NYSE:GMED), a spinal and musculoskeletal medical device company, reported its Q2 2025 earnings on August 7, 2025. The main highlight was a jump in headline net income (GAAP) in Q2 2025, driven by unique, non-operational items such as a major acquisition gain and a one-time tax benefit. Reported revenue (GAAP) was $745.3 million, surpassing the analyst estimate of $741.1 million. Non-GAAP earnings per share (EPS) landed at $0.86, outpacing the $0.75 estimate. Under the surface, core U.S. Spine business delivered growth of 5.7% (as reported), Enabling Technologies revenue (GAAP) dipped, and adjusted profit margins (non-GAAP, as a percentage of net sales) compressed somewhat. The company reaffirmed its annual guidance for fiscal 2025, projecting revenue in the range of $2.80 to $2.90 billion and non-GAAP fully diluted EPS between $3.00 and $3.30, signaling management’s continued confidence, but did not provide an upward revision following the modest beat this period.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q2 2025 earnings report.
Globus Medical develops and sells devices for treating musculoskeletal disorders, with a focus on spinal surgeries and orthopedic problems. Its core business includes spinal implants, surgical instruments, robotics, and enabling technologies for navigation and planning.
Source Fool.com
